Enovis Corp (ENOV) Stock Price & Analysis
Enovis Corp (ENOV) rose 3.72% to USD 27.03 as of July 25, 2026 at 16:30 UTC, according to Nexqual real-time market data.
ENOV last closed at USD 26.06; the session ranged USD 25.84–27.17 on volume of 708,831 shares. Market capitalization is $1.56B, with a 52-week range of USD 19.14–34.28 (NYQ). Source: Nexqual, July 25, 2026 at 16:30 UTC.
Key Statistics (as of July 25, 2026 at 16:30 UTC)
| Price | USD 27.03 |
|---|---|
| Change | ▲ 3.72% (up) |
| Previous Close | USD 26.06 |
| Open | USD 26.26 |
| Day Range | USD 25.84 – 27.17 |
| 52-Week Range | USD 19.14 – 34.28 |
| Volume | 708,831 shares |
| Market Cap | $1.56B |
| Exchange | NYQ |
Technical Analysis (ENOV)
Nexqual's technical model rates ENOV "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 16:30 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 57.32 (neutral) |
| vs SMA50 | Above (USD 23.81) |
| MACD | 1.09 (positive) |
Analyst Ratings (ENOV)
Wall Street analysts rate ENOV "Strong Buy" based on 11 analysts, with a mean price target of USD 40.73 (range USD 29–55), per Nexqual as of July 25, 2026 at 16:30 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 40.73 |
| High Target | USD 55 |
| Low Target | USD 29 |
| Buy / Hold / Sell | 11 / 1 / 0 |
Earnings (ENOV)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 0.85 |
| Revenue Estimate | $582.45M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.89 vs est 0.81 ▲ beat |
| 2025-12-31 | USD 0.95 vs est 0.84 ▲ beat |
| 2025-09-30 | USD 0.75 vs est 0.65 ▲ beat |
| 2025-06-30 | USD 0.79 vs est 0.72 ▲ beat |
Source: Nexqual, July 25, 2026 at 16:30 UTC.
Financials & Fundamentals (ENOV)
| Total Revenue | $2.28B |
|---|---|
| Revenue Growth (YoY) | +5.40% |
| Gross Margin | +61.00% |
| Operating Margin | +3.64% |
| Profit Margin | -49.91% |
| ROE | -55.35% |
| Debt / Equity | 95.34 |
| Current Ratio | 2.04 |
| Total Cash | $33.13M |
| Total Debt | $1.41B |
| Free Cash Flow | $206.90M |
Source: Nexqual, July 25, 2026 at 16:30 UTC.
Financial Health Score (ENOV)
Nexqual rates Enovis Corp's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 16:30 UTC.
| Growth | Solid — Revenue +7% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 61%, operating 4% |
| Balance Sheet | Mixed — $33M cash vs $1.41B debt |
| Cash Flow | Solid — FCF $207M, 9% margin |
| Efficiency | Critical — ROE -55%, ROA 1.1% |
Ownership (ENOV)
| Insider Ownership | +1.63% |
|---|---|
| Institutional Ownership | +121.12% |
| Shares Outstanding | 57.56M |
| Float | 56.59M |
| Short % of Float | +17.28% |
Source: Nexqual, July 25, 2026 at 16:30 UTC.
Leadership (ENOV)
Enovis Corp is led by Damien McDonald (age 60), CEO & Director, per Nexqual as of July 25, 2026 at 16:30 UTC.
| CEO & Director | Damien McDonald (age 60) |
|---|---|
| Senior VP & CFO | Phillip Benjamin Berry (age 46) |
| Group President Prevention & Recovery | Terry D. Ross (age 55) |
| Group President of Reconstructive | Louie Vogt (age 44) |
| Vice President of Investor Relations | Kyle William Rose |
Major Backers & Investors (ENOV)
Notable institutional backers of Enovis Corp include American Century Companies Inc, Rubric Capital Management LP, Davenport & Co LLC, according to Nexqual as of July 25, 2026 at 16:30 UTC.
Active Investors
| Investor | Stake |
|---|---|
| American Century Companies Inc | 14.39% |
| Rubric Capital Management LP | 4.26% |
| Davenport & Co LLC | 4.07% |
| Paradigm Capital Management | 3.09% |
| Hood River Capital Management LLC | 3.05% |
| Fidelity | 2.49% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 25.65% |
| Vanguard Group | 17.96% |
| Dimensional Fund Advisors | 4.42% |
| State Street | 4.17% |
Source: Nexqual, July 25, 2026 at 16:30 UTC.
From Enovis Corp's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Class I includes devices with the lowest patient risk and are those for which safety and effectiveness can be assured by adherence to the FDA's general controls for medical devices, including compliance with applicable portions of the Quality System Regulation ("QSR") facility registration and product listing, reporting of adverse medical events, and truthful and non-misleading labeling, advertising, and promotional materials.
- We serve orthopedic surgeons and healthcare systems worldwide with products for shoulder, hip, knee, and extremity reconstruction and fixation, including both primary and revision procedures. 4 Our offerings are supported by proprietary surgical techniques, surgeon education, and digital tools that enhance preoperative planning, intraoperative precision, and postoperative recovery.
- The comprehensive range of products we offer enables us to reach a diverse customer base through multiple distribution channels with numerous opportunities to increase our growth across our markets.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ESAB | ESAB Corporation | USD 84.44 | ▲ 0.49% |
| AZTA | Azenta, Inc. | USD 27.37 | ▲ 0.77% |
| EPAC | Enerpac Tool Group Corp. | USD 34.67 | ▲ 0.14% |
| ZWS | Zurn Elkay Water Solutions Corp | USD 48.38 | ▲ 1.9% |
| LIVN | LivaNova PLC | USD 78.19 | ▼ 0.1% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 16:30 UTC. This page is informational and not investment advice.